Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Health Canada warns of benzocaine risk; Perrigo first with store-brand Mucinex; NAD enters Glaxo/Colgate toothpaste war; Sun Capital snags supplement manufacturer CornerStone; more news In Brief.

You may also be interested in...



NARB Upholds NAD Recommendations For Colgate Sensitive Ads

The Council of Better Business Bureaus appeals board agrees that testing does not support claims that Colgate Sensitive Pro-Relief is “faster” and “better” than GlaxoSmithKline's Sensodyne. Colgate argued its studies were sufficient, having incorporated industry-standard methodology accepted by FDA and the ADA.

Colgate Bids To Expand U.S. Toothpaste Lineup Through FDA Rulemaking

Colgate seeks regulatory approval for a version of its Colgate Sensitive Multi-Protection toothpaste in a formulation it already markets internationally. The request made in a citizen petition comes after Colgate’s plan to expand its U.S. toothpaste business failed when FDA did not give approval for Sensitive Pro-Relief.

Perrigo Sets Generic Mucinex Launch After Patent Claim Decision

The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel